HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MEDI0457

DNA immunotherapy targeting HPV16/18 E6/E7 with IL12 encoding plasmids

Also Known As:

INO-3112

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - Papillomavirus Vaccines: 3037
        MEDI0457: 6

Experts

1.	Boyer, Jean: 2 articles (01/2020 - 01/2019)
2.	Esser, Mark: 2 articles (01/2020 - 01/2019)
3.	Kumar, Rakesh: 2 articles (01/2020 - 01/2019)
4.	Arif, Fauzia: 1 article (01/2020)
5.	Bagarazzi, Mark: 1 article (01/2020)
6.	Brooks, Rebecca: 1 article (01/2020)
7.	Fleming, Gini: 1 article (01/2020)
8.	Furtado, Larissa: 1 article (01/2020)
9.	Golden, Daniel: 1 article (01/2020)
10.	Hasan, Yasmin: 1 article (01/2020)

Related Diseases

1.	Squamous Cell Carcinoma of Head and Neck 01/01/2023 - "Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma." 07/14/2023 - "MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Letter." 07/14/2023 - "MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response." 01/01/2023 - "We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined with the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response and improve outcomes in recurrent/metastatic HPV-16/18-associated HNSCC. "
2.	Neoplasms (Cancer) 01/01/2019 - "MEDI0457 shifted the CD8+/FoxP3+ ratio in 4 of 5 post immunotherapy tumor samples and increased the number of perforin+ immune infiltrates in all 5 patients. " 01/01/2023 - "Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers." 01/01/2023 - "The combination of MEDI0457 and durvalumab demonstrated acceptable safety and tolerability in patients with advanced HPV-16/18 cancers. " 01/01/2023 - "We tested MEDI0457 with the anti-PD-L1 antibody durvalumab for patients with HPV-associated cancers. " 01/01/2019 - "These data demonstrate that MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. "
3.	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/01/2020 - "Ten patients (cohort 1, n = 7; cohort 2, n = 3) with HPV16 (n = 7) or HPV18 (n = 3) cervical cancers received MEDI0457 after chemoradiation. " 01/01/2020 - "At 2 to 4 weeks after chemoradiation, patients with newly diagnosed stage IB1-IVA (cohort 1) or persistent/recurrent (cohort 2) cervical cancers were treated with 4 immunizations of MEDI0457 every 4 weeks. " 01/01/2020 - "Adjuvant MEDI0457 is safe and well tolerated after chemoradiation for locally advanced or recurrent cervical cancers, supporting further investigation into combining tumor-specific vaccines with radiation therapy."
4.	Injection Site Reaction 01/01/2019 - "MEDI0457 was associated with mild injection site reactions, but no treatment-related grade 3-5 adverse events (AE) were noted. "

Related Drugs and Biologics

1.	durvalumab
2.	Vaccines
3.	A-Form DNA (A-DNA)
4.	Interleukin-12 (IL 12)
5.	Antigens
6.	Immune Checkpoint Inhibitors

Related Therapies and Procedures

1.	Radiotherapy
2.	Immunotherapy